Updated: Jul 2026
86%
of employees say this is a great place to work
Our core business is the development and marketing of medicines. Currently, over 275,000 people in Switzerland are being treated with an AstraZeneca medicine. Between 2026 and 2028, the company expects over 40 new therapies to be approved. We
We always strive to contribute to making the Swiss healthcare system more sustainable, robust, and fit for future challenges. With this goal in mind, we work with various stakeholders – far beyond our core business.
(Zug)
Certification July 2026
Certification June 2025
Certification May 2024
Certification February 2023
Certification April 2021
Certification March 2020
Certification March 2019
Certification July 2026
Certification June 2025
Certification May 2024
Certification February 2023
Certification April 2021
Certification March 2020
Certification March 2019
You are currently viewing placeholder content from Vimeo. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing placeholder content from reCAPTCHA. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information
